

## AMENDMENTS TO THE CLAIMS

Please cancel claim 105.

Please amend claims 88, 92-95 as follows:

D<sup>1</sup> 88. (Amended) An immunogenic composition comprising an isolated immunogenic hepatitis C virus (HCV) polypeptide [in substantially isolated form] wherein said immunogenic polypeptide comprises a region selected from the group consisting of an envelope polypeptide encoded by an envelope domain of an HCV genome and immunogenic fragments of said envelope polypeptide.

92. (Amended) An immunogenic composition according to claim 88 further comprising an isolated immunogenic HCV polypeptide wherein said immunogenic polypeptide comprises a region selected from the group consisting of a core polypeptide encoded by a core domain of an HCV genome and immunogenic fragments of said core polypeptide.

D<sup>2</sup> 93. (Amended) An immunogenic composition comprising an isolated immunogenic HCV polypeptide wherein said polypeptide comprises a region selected from the group consisting of a core polypeptide encoded by a core domain of an HCV genome and immunogenic fragments of said core polypeptide.

94. (Amended) An immunogenic composition comprising an isolated immunogenic HCV polypeptide wherein said polypeptide comprises a region selected from the group consisting of a NS1 polypeptide encoded by a NS1 domain of an HCV genome and immunogenic fragments of said NS1 polypeptide.

95. (Amended) An immunogenic composition comprising an isolated immunogenic HCV polypeptide wherein said polypeptide comprises a region selected from the group consisting of a NS1 polypeptide encoded by a NS2 domain of an HCV genome and immunogenic fragments of said NS2 polypeptide.

## REMARKS

Claim 105 has been cancelled. Claims 88 -104 and 106-114 are pending. With respect to the cancelled claim, Applicants do not concede that these claims are not patentable and reserve